UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Colloids and surfaces, B, Biointerfaces, ISSN 0927-7765, 10/2016, Volume 146, pp. 852 - 860
Hydroxyapatite nanoparticles | Sustained delivery | Bendamustine Hydrochloride | Synergism | Cancer therapy | Physical Sciences | Chemistry | Materials Science | Life Sciences & Biomedicine | Technology | Materials Science, Biomaterials | Biophysics | Chemistry, Physical | Science & Technology | Nanoparticles - chemistry | Rats, Wistar | Apoptosis - drug effects | Humans | Drug Carriers - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Drug Delivery Systems | Bendamustine Hydrochloride - administration & dosage | Durapatite - administration & dosage | Durapatite - pharmacology | Antineoplastic Agents - pharmacology | Carcinoma, Ehrlich Tumor - pathology | Jurkat Cells | Rats | Carcinoma, Ehrlich Tumor - drug therapy | Durapatite - chemistry | Antineoplastic Agents - chemistry | Animals | Bendamustine Hydrochloride - pharmacology | Bendamustine Hydrochloride - chemistry | Mice | Mice, Inbred BALB C | Nanoparticles - administration & dosage | In Vitro Techniques | Nanoparticles | Antimitotic agents | Care and treatment | Antineoplastic agents | Cancer | Adsorption | Analysis | Precipitation (Meteorology) | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Evidence-based medicine | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, 04/2017, Volume 113, pp. 198 - 210
Cell uptake | Bendamustine hydrochloride | DLS | Reverse micelle | Monocyte targeting | AOT | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Microscopy, Electron, Transmission | Phagocytosis - drug effects | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Endocytosis - drug effects | Humans | Antineoplastic Agents, Alkylating - pharmacology | Antineoplastic Agents, Alkylating - administration & dosage | Drug Carriers | Nanoparticles | Bendamustine Hydrochloride - administration & dosage | Bendamustine Hydrochloride - pharmacology | Micelles | Cell Cycle - drug effects | Cell Line, Transformed | Fluorescent Dyes | Antimitotic agents | Antineoplastic agents | Pharmaceutical industry | Leukemia | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 08/2007, Volume 110, Issue 4, pp. 861 - 866
Refractory | Soft tissue sarcoma | Bendamustine hydrochloride | Second-line | Alkylating agents | Tumors of the skin and soft tissue. Premalignant lesions | Biological and medical sciences | Medical sciences | Dermatology | Tumors | Drug Administration Schedule | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Anemia - chemically induced | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Sarcoma - drug therapy | Sarcoma - pathology | Fever - chemically induced | Nitrogen Mustard Compounds - adverse effects | Bendamustine Hydrochloride | Nitrogen Mustard Compounds - therapeutic use | Antineoplastic Agents - adverse effects | Adolescent | Adult | Female | Aged | Infusions, Intravenous | Neutropenia - chemically induced | Care and treatment | Sarcoma | Physiological aspects | Dosage and administration | Diagnosis | Research | Statistics | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4, pp. 269 - 277
Oncology | Cancer Research | Life Sciences & Biomedicine | Science & Technology | Recurrence | Drug Administration Schedule | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Neoplasm, Residual | Rituximab - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Sulfonamides - adverse effects | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Rituximab - adverse effects | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1932 - 1938
relapsed/refractory NHL | phase Ib | venetoclax | bendamustine-rituximab | Salvage Therapy - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Rituximab - pharmacokinetics | Bendamustine Hydrochloride - adverse effects | Chemotherapy-Induced Febrile Neutropenia - etiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Bendamustine Hydrochloride - pharmacokinetics | Lymphoma, Non-Hodgkin - pathology | Neoplasm Recurrence, Local - pathology | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Rituximab - adverse effects | Chemotherapy-Induced Febrile Neutropenia - epidemiology | Drug Administration Schedule | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Disease Progression | Sulfonamides - pharmacokinetics | Rituximab - administration & dosage | Maximum Tolerated Dose | Progression-Free Survival | Sulfonamides - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Salvage Therapy - methods | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Drug Resistance, Neoplasm - drug effects | Index Medicus | relapsed | refractory NHL | Original | bendamustine–rituximab
Journal Article
British journal of cancer, ISSN 0007-0920, 06/2007, Volume 96, Issue 11, pp. 1692 - 1698
Bendamustine | Phase I | Pharmacokinetics | Day 1 + 2 schedule | Drug Administration Schedule | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Nitrogen Mustard Compounds - pharmacokinetics | Nitrogen Mustard Compounds - urine | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Nitrogen Mustard Compounds - adverse effects | Neoplasms - drug therapy | Bendamustine Hydrochloride | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aged | Index Medicus | pharmacokinetics | day 1+2 schedule | Translational Therapeutics | phase I | bendamustine
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 27, pp. 3293 - 3299
Life Sciences & Biomedicine | Oncology | Science & Technology | Antigens, CD34 - metabolism | Prospective Studies | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Young Adult | Bendamustine Hydrochloride - administration & dosage | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Deoxycytidine - adverse effects | Female | Hematopoietic Stem Cell Mobilization | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Hematopoietic Stem Cell Transplantation - methods | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
The Lancet. Haematology, ISSN 2352-3026, 2016, Volume 4, Issue 1, pp. e15 - e23
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Hematology | Science & Technology | Bendamustine Hydrochloride - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bendamustine Hydrochloride - adverse effects | Cytarabine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Cytarabine - adverse effects | Cytarabine - administration & dosage | Rituximab - administration & dosage | Rituximab - therapeutic use | Bendamustine Hydrochloride - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Female | Italy - epidemiology | Aged | Lymphoma, Mantle-Cell - epidemiology | Rituximab - adverse effects | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. 1215 - 1228
Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Prospective Studies | Drug Administration Schedule | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Germany | Sulfonamides - administration & dosage | Analysis | Bendamustine | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 07/2018, Volume 132, Issue 1, pp. 40 - 48
Life Sciences & Biomedicine | Hematology | Science & Technology | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bendamustine Hydrochloride - adverse effects | Hodgkin Disease - pathology | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Survival Rate | Immunoconjugates - administration & dosage | Disease-Free Survival | Bendamustine Hydrochloride - administration & dosage | Time Factors | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Aged | Immunoconjugates - adverse effects | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article